Recently, phase I/II cancer clinical trials have been launched to assess the role of ATR inhibitors, either as single agents or in combinations with chemotherapy, radiotherapy, and immunotherapy in patients with advanced and refractory solid tumors (clinicaltrials.gov and [97]), with the first results reported [98,99,100,101]. The gene discussed is ATR; the disease is cancer.